ClinicalTrials.gg
RecruitingNCT05287126Updated Oct 27, 2026

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

A Phase 2 interventional study of Etrasimod in Ulcerative Colitis, sponsored by Pfizer. Recruiting at 47 sites in 5 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Oct 27, 2026Site recruiting status changed3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.

Planned enrollment
11th of 12
36 · median 195
Started
2022
the only one that year
Phase 2
6 of 12
2 open now
Registered
10th of 12
by date
Lead sponsor
6 of 12
Pfizer

Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 11th largest by planned enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 10th registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etrasimod

etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing etrasimod in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Pharmacokinetics
  • Adolescents
  • Active Ulcerative Colitis
  • APD334
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of ulcerative colitis (UC) that is moderately to severely active
  • Participants are permitted to be receiving a therapeutic dose of select UC therapies

Exclusion criteria

Exclusion criteria:

  • Severe extensive colitis
  • Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
  • Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Etrasimod

    Drug: Etrasimod

Interventions

  • Etrasimod tablet or granules by mouth, once daily up to 52 weeks of treatment.

    Also known as: APD334

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score (MMS) at Week 52

    Time frame: Week 52

Secondary outcomes

  1. Plasma Concentration of Etrasimod at 4 Hours Post-dose (C4h)

    Time frame: 4 hours (± 15 minutes) post-dose

  2. Plasma Steady State Trough Concentration (Ctrough,ss) of Etrasimod

    Time frame: pre-dose and 4 hours (±15 minutes) post-dose at Day 1; at trough concentrations (approximately 24 hours after the dose taken the day before the study visit) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52

  3. Proportion of Participants Achieving Clinical Remission as Assessed by MMS at Week 12

    Time frame: Week 12

  4. Proportion of Participants Achieving Endoscopic Improvement at Week 12

    Time frame: Week 12

  5. Proportion of Participants Achieving Endoscopic Improvement at Week 52

    Time frame: Week 52

  6. Proportion of Participants Achieving Symptomatic Remission at Week 12

    Time frame: Week 12

  7. Proportion of Participants Achieving Symptomatic Remission at Week 52

    Time frame: Week 52

  8. Proportion of Participants with Clinical Remission at Week 12 Who Had Not been Receiving Corticosteroids for ≥ 2 weeks Prior to Week 12

    Time frame: Week 12

  9. Proportion of Participants with Clinical Remission at Week 52 Who Had Not been Receiving Corticosteroids for ≥ 12 weeks Prior to Week 52

    Time frame: Week 52

  10. Proportion of Participants Achieving Clinical Response at Week 12

    Time frame: Week 12

  11. Proportion of Participants Achieving Clinical Response at Week 52

    Time frame: Week 52

  12. Proportion of Participants Achieving Clinical Remission by Pediatric Ulcerative Colitis Activity Index (PUCAI) at Week 12

    Time frame: Week 12

  13. Proportion of Participants Achieving Clinical Remission as Assessed by PUCAI at Week 52

    Time frame: Week 52

  14. Proportion of Participants Achieving a Clinical Response as Assessed by PUCAI at Week 12

    Time frame: Week 12

  15. Proportion of Participants Achieving a Clinical Response as Assessed by PUCAI at Week 52

    Time frame: Week 52

  16. Number and Severity of Adverse Events

    Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.

    Time frame: Up to Week 52

07

Study locations

39 of 47 sites recruiting
  • Arkansas Children's (IP Address)
    Little Rock, Arkansas 72202, United States
    Not yet recruiting
  • Arkansas Children's
    Little Rock, Arkansas 72202, United States
    Not yet recruiting
  • Valley View Wellness Medical Center
    Garden Grove, California 92845, United States
    Recruiting
  • Loma Linda Children's Hospital
    Loma Linda, California 92354, United States
    Not yet recruiting
  • Loma Linda University Clinical Trial Center
    Loma Linda, California 92354, United States
    Not yet recruiting
  • Loma Linda University Eye Institute
    Loma Linda, California 92354, United States
    Not yet recruiting
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
    Not yet recruiting
  • Loma Linda University Pediatric Clinics
    Loma Linda, California 92354, United States
    Not yet recruiting
  • Loma Linda University Children's Hospital Pediatric Specialty Clinics
    San Bernardino, California 92408, United States
    Not yet recruiting
  • University of California San Francisco,
    San Francisco, California 94158, United States
    Recruiting
  • University of California San Francisco
    San Francisco, California 94158, United States
    Recruiting
  • University of California,San Francisco Pediatric ClinicalResearch Center (PCRC)
    San Francisco, California 94158, United States
    Recruiting
  • Arnold Palmer Hospital - Center for Digestive Health and Nutrition
    Orlando, Florida 32806, United States
    Recruiting
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
  • William Beaumont Hospital/Corewell Health - East
    Royal Oak, Michigan 48073, United States
    Recruiting
  • William Beaumont Hospitals Reference Laboratory
    Royal Oak, Michigan 48073, United States
    Recruiting
  • University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital
    Cleveland, Ohio 44106, United States
    Recruiting
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
  • ACT-Midwest G1
    Abilene, Texas 79606, United States
    Recruiting
  • Cook Children's Health Care System-Dodson Specialty Clinics
    Fort Worth, Texas 76104, United States
    Recruiting
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
    Recruiting
  • Tsujinaka Hospital - Kashiwanoha
    Kashiwa, Chiba 277-0871, Japan
    Recruiting
  • Ishii Eye Clinic
    Nagareyama-shi, Chiba 270-0116, Japan
    Recruiting
  • Gunma University Hospital
    Maebashi, Gunma 371-8511, Japan
    Recruiting
  • Hyogo Medical University Hospital
    Nishinomiya, Hyōgo 663-8501, Japan
    Recruiting
  • Kinki University - Nara Hospital
    Ikoma, Nara 630-0293, Japan
    Recruiting
  • Saitama Prefectural Children's Medical Center
    Saitama-shi, Saitama 330-8777, Japan
    Recruiting
  • Jichi Medical University Hospital
    Shimotsuke, Tochigi 329 0498, Japan
    Recruiting
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
    Recruiting
  • Japanese Red Cross Kyoto Daini Hospital
    Kyoto, 602-8026, Japan
    Recruiting
  • Saga University Hospital
    Saga, 849-8501, Japan
    Recruiting
  • Toyama Prefectural Central Hospital
    Toyama, 930-8550, Japan
    Recruiting
  • WIP Warsaw IBD Point Profesor Kierkuś
    Warsaw, Masovian Voivodeship 04-501, Poland
    Recruiting
  • Instytut "Pomnik - Centrum Zdrowia Dziecka" (IPCZD) (The Children's Memorial Health Institute)
    Warsaw, Masovian Voivodeship 04-730, Poland
    Recruiting
  • Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero
    Katowice, 40-600, Poland
    Recruiting
  • Uniwersytecki Szpital Dziecięcy w Krakowie
    Krakow, 30-663, Poland
    Recruiting
  • Twoja Przychodnia - Szczecińskie Centrum Medyczne
    Szczecin, 71-434, Poland
    Recruiting
  • Centrum Zdrowia MDM
    Warsaw, 00-189, Poland
    Recruiting
  • WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, 00-728, Poland
    Recruiting
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
    Wroclaw, 50-369, Poland
    Recruiting
  • Detska fakultna nemocnica Kosice
    Košice, 040 11, Slovakia
    Recruiting
  • K.M. Management, spol. s r.o.
    Nitra, 949 01, Slovakia
    Recruiting
  • Hospital Clinico Universitario de Santiago de Compostela
    Santiago de Compostela, A Coruna 15706, Spain
    Recruiting
  • Consorci Corporacio Sanitaria Parc Tauli
    Sabadell, Barcelona 08208, Spain
    Recruiting
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
  • Hospital Reina Sofia
    Córdoba, 14004, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Jun 2029, 78 months after the start.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 78 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Mar 18, 2022
StartActual
Dec 16, 2022
Primary completionEst.
Jun 16, 2029
CompletionEst.
Jul 10, 2033
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed. Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero is now Recruiting
Show 3 added (2 United States, 1 Slovakia)
  • Cook Children's Health Care System-Dodson Specialty Clinics · Fort Worth, United States
  • Cook Children's Medical Center · Fort Worth, United States
  • Detska fakultna nemocnica Kosice · Košice, Slovakia
Show 1 removed
  • Instytut Centrum Zdrowia Matki Polki · Lodz, Poland
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    3 sites added, 1 site removed. Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero is now Recruiting
    Show 3 added (2 United States, 1 Slovakia)
    • Cook Children's Health Care System-Dodson Specialty Clinics · Fort Worth, United States
    • Cook Children's Medical Center · Fort Worth, United States
    • Detska fakultna nemocnica Kosice · Košice, Slovakia
    Show 1 removed
    • Instytut Centrum Zdrowia Matki Polki · Lodz, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05287126
Lead sponsor
Pfizer
Collaborators
Arena is a wholly owned subsidiary of Pfizer
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Dec 16, 2022
Primary completion
Jun 16, 2029 (estimated)
Completion
Jul 10, 2033 (estimated)
Last update
Oct 27, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion